PatientsVille.com Logo


Ambisome Medical Research Studies

Up-to-date List of Ambisome Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Ambisome Medical Research Studies

Rank Status Study
1 Unknown  Phase III, Study of Three Short Course Combination Regimens (Ambisome®, Miltefosine, Paromomycin) Compared With Ambisome® Alone for the Treatment of Visceral Leishmaniasis in Bangladesh
Condition: Visceral Leishmaniasis
Interventions: Drug: Liposomal amphotericin B;   Drug: liposomal amphotericin B + miltefosine;   Drug: liposomal amphotericin B + paromomycin;   Drug: Miltefosine + Paromomycin
Outcome Measures: Definitive cure;   Initial Cure;   Adverse events
2 Not yet recruiting Efficacy Trial of Ambisome Given Alone and Ambisome Given in Combination With Miltefosine for the Treatment of VL HIV Positive Ethiopian Patients.
Condition: Visceral Leishmaniasis
Interventions: Drug: Liposomal Amphotericin B;   Drug: Miltefosine
Outcome Measures: Initial parasitological cure at day 29;   Relapse-free survival at day 390
3 Unknown  Clinical Trial to Assess the Safety and Efficacy of Sodium Stibogluconate (SSG) and Ambisome® Combination, Miltefosine and Ambisome® and Miltefosine Alone for the Treatment Visceral Leishmaniasis in Eastern Africa
Condition: Primary Visceral Leishmaniasis
Interventions: Drug: Liposomal amphotericin B (Ambisome®) and sodium stibogluconate;   Drug: Liposomal amphotericin B + miltefosine;   Drug: Miltefosine
Outcome Measures: Initial cure: proportion cured at Day 28;   Final cure: proportion cured at day 210;   Adverse events and serious adverse events occurring in the three study arms
4 Recruiting Liposomal Amphotericin B for the Treatment of Cryptococcal Meningitis
Condition: Cryptococcal Meningitis
Interventions: Drug: Liposomal amphotericin B;   Drug: Amphotericin B-deoxycholate
Outcome Measure: suscceful response rate
5 Not yet recruiting Single Dose Liposomal Amphotericin B for Visceral Leishmaniasis
Condition: Visceral Leishmaniasis
Intervention: Drug: Ambisome
Outcome Measure: CLINICAL CURE
6 Unknown  Ambisome® Preemptive Treatment of Multiple Candida Colonization in Sepsis Patients
Conditions: Sepsis;   Candida
Intervention: Drug: Amphotericine in liposome (Ambisome®)
Outcome Measures: Global assessment of severity of adverse events; incidence, severity and consequences of treatment emergent effects;   Duration of stay in the intensive care unit; occurrence of a systemic fungal infection
7 Unknown  Antifungal Locks to Treat Fungal-Related Central Line Infections
Condition: Central Line Fungal Infections
Intervention: Drug: amphotericin B liposomal (Ambisome)
Outcome Measures: The success of antifungal lock therapy (the primary endpoint) will be determined by whether or not the patient has at least 2 negative fungal cultures and the CVC was not removed.;   The number of days before the infected central line culture becomes negative;   The development of fungal-related complications;   Test of cure catheter cultures on day 5 and day 30 post antifungal lock
8 Recruiting Study to Compare the Efficacy and Safety of Micafungin Versus Conventional Amphotericin B for the Treatment of Neonatal Candidiasis
Condition: Candidiasis
Interventions: Drug: micafungin;   Drug: amphotericin B deoxycholate
Outcome Measures: Fungal free survival;   Time to mycological clearance of invasive candidiasis;   Fungal free survival in infants with end-organ dissemination at end of study drug therapy;   Fungal free survival in infants with end-organ dissemination one week after last dose of study drug;   Overall incidence of emergent fungal infections through the end of study;   Overall incidence of recurrent fungal infections through the end of study;   Time to positive clinical response (complete or partial);   Clinical response (complete, partial, stabilization, progression) at the end of study drug therapy;   Clinical response (complete, partial, stabilization, progression) one week after last dose of study drug;   Mycological response at end of study drug therapy;   Mycological response one week after last dose of study drug;   Status of follow-up imaging and exams (improved, stable, worse) for infants with end-organ assessments;   Pharmacokinetics model parameters
9 Recruiting Topical 3% Amphotericin B Cream for the Treatment of Cutaneous Leishmaniasis in Colombia
Condition: Cutaneous Leishmaniasis
Intervention: Drug: Topical Amphotericin B at 3%
Outcome Measures: Proportion and severity of local adverse events of Anfoleish or Vehicle when applied three or two times per day.;   Clinical cure rates in two regimens of Anfoleish: Three times a day and Two times a day;   Determination of Amphotericin B Cmax and Tmax in subjects treated with Anfoleish three or two times per day.;   Proportion and severity of laboratory adverse events of Anfoleish or vehicle when applied three or two times per day
10 Recruiting Safety, Tolerability, and Efficacy of Caspofungin Versus Amphotericin B Deoxycholate in the Treatment of Invasive Candidiasis in Neonates and Infants (MK-0991-064)
Condition: Candidiasis, Invasive
Interventions: Drug: Caspofungin;   Drug: Amphotericin B Deoxycholate
Outcome Measures: Percentage of Participants with Fungal-free Survival Through the 2-week Posttherapy Period;   Percentage of Participants with Fungal-free Survival Through the End of Study Treatment
11 Recruiting Intermittent Liposomal Amphotericin B Primary Prophylaxis
Condition: Acute Myeloid Leukemia
Intervention: Drug: Liposomal amphotericin B
Outcome Measures: Safety as defined by the incidence of all adverse events occurring by the completion of each trial prophylaxis course.;   Safety:;   Incidence of renal toxicity;   Incidence of hepatotoxicity;   Incidence of ionic abnormalitities;   Incidence of cardiovascular toxicity;   Efficacy:;   Incidence of proven or probable IFI;   Incidence of superficial fungal infections;   Incidence of fever of unknown origin requiring empirical antifungal therapy during any course of prophylaxis;   Incidence of IFI-related mortality
12 Recruiting A Randomized Controlled Trial of Inhaled Amphotericin B for Maintaining Remission in Allergic Bronchopulmonary Aspergillosis
Condition: Allergic Bronchopulmonary Aspergillosis
Interventions: Drug: Inhaled budesonide;   Drug: Inhaled amphotericin
Outcome Measures: Time to first relapse;   ACQ-7 scores between the two groups;   Number of asthma exacerbations requiring oral steroids;   Improvement in forced expiratory volume in the first second (FEV1);   Adverse effects of therapy in both the arms
13 Unknown  Antifungal Prophylaxis in Pediatric Acute Leukemia
Condition: Pediatric Acute Leukemia Induction
Intervention: Drug: ORAL VORICONAZOLE and IV Amphotericin B
Outcome Measure: Prevention of possible, probable or proven fungal infection.
14 Unknown  A Double Blind Randomised Study of Lapatinib and Placebo in Metastatic TCC of the Urothelium
Condition: Bladder Cancer
Interventions: Drug: lapatinib ditosylate;   Other: Placebo
Outcome Measures: Progression free survival;   Overall survival
15 Unknown  Evaluate Efficacy, Tolerability & Safety of Combination of Clindamycin and Ketoconazole for the Treatment of Mixed-Type Vaginosis, Bacterial Vaginosis and Candidiasis
Conditions: Candidiasis;   Bacterial Vaginosis
Interventions: Drug: Clindamycin 100mg and Ketoconazole 400mg;   Drug: Tetracycline 100mg and Amphotericin B 50mg
Outcome Measures: Efficacy based on cure rate evaluated by clinical and laboratory criteria.;   Tolerability based on adverse events reports and patient's information;   Safety based on adverse events reports and laboratory criterion
16 Recruiting High-Dose Fluconazole for the Treatment of Cryptococcal Meningitis in HIV-Infected Individuals
Conditions: Cryptococcal Meningitis;   HIV Infections
Interventions: Drug: Fluconazole;   Drug: Amphotericin B
Outcome Measures: Discontinuation of study-provided fluconazole or ampho B, including precipitating and surrounding adverse events;   Qualitative and quantitative CSF culture results at entry, Week 2, and when conducted thereafter;   Survival;   Results of the neurological examination;   Length of hospitalization;   Recurrence/relapse of CM based on clinical presentation;   CNS immune reconstitution inflammatory syndrome (IRIS);   Additional safety parameters including: Grade 3 and 4 adverse events; dose modifications; duration of temporary treatment interruptions; permanent discontinuation of either agent;   Results of functional status evaluation;   Number and nature of hospital readmissions
17 Recruiting Use of Spironolactone for the Prevention of Electrolyte Abnormalities in Patients Treated With Amphotericin B
Condition: Patients With Indications for AmB Treatment
Interventions: Drug: Spironolactone 100mg;   Drug: Spironolactone 200mg;   Drug: Placebo
Outcome Measures: Incidence of hypokalemia ≤3.5mEq/L;   Average potassium supplementation;   Incidence of hyperkalemia;   Acute kidney injury;   Incidence of renal tubular damage;   Incidence of hypomagnesemia
18 Unknown  Value of Amphotericin B Inhalation for Prophylaxis of Invasive Pulmonary Aspergillosis After Renal Transplantation
Condition: Invasive Pulmonary Aspergillosis
Intervention: Drug: Amphotericin B
Outcome Measure: invasive pulmonary aspergillosis
19 Recruiting LA Moms and Babies Study (LAMBS) for Nutrition and Growth
Conditions: Pregnancy;   Inflammation
Interventions: Dietary Supplement: Capsule 1 or Capsule 2;   Dietary Supplement: Capsule 2
Outcome Measures: Differences in maternal inflammation between the two study groups.;   Differences in infant growth will be determined with measurements of infant height and weight and with an instrument that determines air displaced by the baby's body.
20 Recruiting International Pediatric Fungal Network
Condition: Pediatric Invasive Candidiasis
Intervention: Drug: Observational antifungal therapy
Outcome Measures: Global response to antifungal therapy at day 14;   Global response of antifungal therapy at day 35;   All-cause mortality;   Development of candidemia while in PICU

These studies may lead to new treatments and are adding insight into Ambisome etiology and treatment.

A major focus of Ambisome research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Ambisome